GSK stock price forecast: GBX2,012.00 resistance in focus as GSK advances 1.17%

Traders Union
All News
Financial News
GSK rises 1.17% to GBX 1,894.50

Highlights

GSK Pharma's Q4 net profit reached Rs 277.86 crore, contributing to a robust full-year result and bolstering group cash flow visibility.
The proposed Rs 57 per share final dividend for FY26 signals a sustained focus on shareholder returns ahead of the AGM.
Shares remain under short-term selling pressure, with price expected to consolidate between GBX 1,880.00 and GBX 1,905.00 amid weak momentum signals.

Earnings momentum builds as Indian subsidiary outperforms and dividends rise

GSK's recent price action is underpinned by its Indian subsidiary GSK Pharma reporting strong Q4 and full-year FY26 results, with consolidated net profit for the quarter at Rs 277.86 crore and profit after tax reaching Rs 1,012 crore for the financial year. The robust earnings performance highlights sustained operating strength, enhancing visibility into group-level cash flows and supporting demand for GSK shares. In addition, the board’s proposal of a final dividend of Rs 57 per share for FY26 signals an ongoing commitment to capital returns, amplifying investor interest ahead of the upcoming AGM.

Long-term support holds as weak momentum and oversold signals persist

Technically, GSK is trading below both the MA-20 (GBX 1,969.18) and MA-50 (GBX 2,027.75), while remaining above the MA-200 at GBX 1,808.63, which provides longer-term support. The Ichimoku Kijun on the daily timeframe stands at GBX 2,012.00, acting as a key resistance level just above the current market price. Momentum indicators are mixed: the D1 MACD and ADX reflect weak momentum and a bearish tilt, while RSI at 34.65 and CCI at -64.27 indicate persistent oversold conditions. Additionally, D1 BBP shows sellers remain dominant intraday, though oscillators like the Stoch RSI are neutral, pointing to possible divergence as price action strengthens against lagging momentum signals.

Sideways trading expected as upside risks hinge on momentum shift

Over the short term, GSK is expected to trade within a typical volatility band between GBX 1,880.00 and GBX 1,905.00. With weak short-term signals and a low probability (less than 20%) of an uptrend, a sideways price scenario remains the baseline, as the market consolidates near key moving averages and session highs. Should bullish momentum unexpectedly increase, a break above GBX 2,012.00 could open further upside. Conversely, if bearish momentum prevails, GSK may retest or potentially slip below the MA-200 at GBX 1,808.00.

Viktoras Karapetjanc, expert at Traders Union, sees GSK’s robust financial results and strong dividend proposal as positive catalysts for the stock. He believes sustained performance at the subsidiary level underscores fundamental strength and enhances market sentiment. Technical indicators still point to weak momentum, but macro and news flow support further upside if a breakout develops. Karapetjanc adds: “With solid fundamentals and a clear capital return signal, I expect GSK to benefit from renewed investor confidence if price can reclaim the GBX 2,012.00 resistance.”

Earlier, analysts noted that GSK continued to face technical challenges and persistent downside momentum despite solid financial results and supportive corporate actions. The current consolidation near session highs and major averages suggests traders should monitor for a potential shift in momentum, with a decisive break above key resistance likely to determine the next directional move.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.